86 results about "Clotrimazole Vaginal Tablet" patented technology

The invention relates to a vagina swelling metronidazole clotrimazole suppository which comprises an active component consisting of clotrimazole, metronidazole and chlorhexidine acetate, a fat-soluble matrix and a swelling carrier. The metronidazole clotrimazole is fully swelled, so that a medicine-containing layer can be in full contact with the inner wall of the vagina to prevent medicine liquid from flowing out; the swelling metronidazole clotrimazole suppository is an inner and outer layer swelling suppository; and the active component is mixed with different matrixes to prepare an inner layer and an outer layer, so that double effects of quick release and slow release can be achieved. According to the vagina swelling metronidazole clotrimazole suppository provided by the invention, seven unique leading technologies are adopted; and furthermore, the vagina swelling metronidazole clotrimazole suppository has the beneficial effects of preventing the medicine liquid from flowing out, quickly making a response and preventing secondary infection along with long medicine working time and the like.

The invention provides a medicine composition for preventing and treating the fungal disease of a pet rabbit. The medicine composition is prepared from the following components in parts by mass: 3 parts of talcum powder, 2 parts of sulphur powder, 1 part of diaveridine and 0.5 part of clotrimazole. The medicine composition can be used for preventing and treating the fungal disease of the pet rabbit, and inhibiting, preventing and treating the occurrence and the infection of diseases caused by the fungus of the pet rabbit, so that the normal growth and development of the pet rabbit are ensured. Therefore, the medicine composition is suitable for the prevention and the treatment of fungal disease of the pet rabbits and other susceptible animals.

Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and / or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.

The invention relates to a clotrimazole live lactobacillus composition and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The clotrimazole live lactobacillus vaginal tablet disclosed by the invention comprises 500mg of clotrimazole; 1mg of lactobacillus powder; 20mg to 30mg of lactic acid; 8-12mg of calcium lactate; 6-12mg of starch; 200-300mg of cellulose lactose C80; 66mg to 180mg of eudragit-RL30D; 225mg to 314mg of lactose; 170mg to 225mg of microcrystalline cellulose; 70mg of crospovidone; 20mg of colloidal silicon dioxide; and 10 mg of magnesium stearate. The invention provides the clotrimazole live lactobacillus vaginal tablet.